Key Takeaways
- Revenue down 13%, margins up: Turnover fell on lower subsidy rates and zero DAP trading, yet operating margins improved to 7%-11% from 7%-9% a year ago as the company shifted product mix and withdrew discounts.
- Subsidy reset reshapes P&K economics: P&K subsidy rates dropped 24%-38% YoY, compressing sales realization; a new ₹3,500/mt DAP special package announced October 24 provides partial relief but management declined to confirm DAP manufacturing profitability.
- Raw material costs climbing, not cresting: Phosphoric acid rose to $1,060/mt for Q3, ammonia and benzene are on an increasing trend, and management pushed back on any suggestion that input prices have stabilized, citing geopolitical volatility.
- HX Crystal plant is the quarter's structural win: GSFC is now India's sole manufacturer of a 100%-imported product, which will absorb caprolactam output and improve the industrial chemicals sub-segment from breakeven or small loss toward profitability.
- What to watch next quarter: Whether the ₹3,500 DAP package plus 5,00,000-tonne Q3 volume target can offset rising input costs and hold the ₹1,500/tonne EBITDA, and how fast the HX Crystal plant ramps past 100% capacity.
Subsidy & Fertilizer Economics
- Subsidy rate compression: Ammonium Sulphate subsidy fell 38% YoY, APS 35%, DAP 24%, directly reducing P&K fertilizer sales realization and driving the 13% revenue decline.
- DAP manufacturing abandoned for now: Management confirmed DAP was not cost-economical to produce by purchasing phosphoric acid, so production shifted to APS and other NPK grades at Sikka; Q2 had zero DAP trading, which alone contributed materially to the revenue drop.
- One-time DAP package: The government declared a special package of ₹3,500 per metric ton on October 24, effective October 1, and is pushing industry to supply more DAP; the company has finalized import contracts for ~1.25 lakh metric tons for the upcoming quarter.
- DAP profitability still uncertain: When asked whether the ₹3,500 package would make DAP manufacturing profitable, management declined to confirm, stating that is precisely why production shifted to APS.
- Urea fixed-cost revision pending: The government is in the process of revising urea fixed costs and has asked all industries for data; management has submitted its data but gave no timeline or quantum, calling it a "let us see" situation.
- Subsidy receipts timely: The government is prompt in releasing subsidy; the company has received subsidy up to the second week of October.
Management: "Profits are not at the level. That is why I told that we shifted already to the APS production in place of DAP. That is as simple as this."
Margin & Cost Structure
- Operating margin improved despite revenue decline: Margins rose from 7%-11% in Q2 last year to 7%-9% in H1, driven by higher capacity utilization, increased sales of manufactured products, and optimized product mix.
- Raw material costs trending up: Phosphoric acid reached $1,060/mt for Q3 vs $948/mt in Q2; ammonia and phosphoric acid pricing internationally is on an increasing trend; raw material cost dropped 1.5% sequentially but management warned this may not sustain.
- Employee cost spike is one-time: Employee costs rose ~₹50 crores due to pay revision adjustments and bonus payments; management characterized this as not a regular feature.
- Other expenses stable: Quarterly other expenses held at ~₹234 crores, half-yearly at ₹443 crores, with no material change.
- Other income is temporary float, not investment yield: The ₹150 crores of other income mostly comprises dividends from other companies and interest on excess funds temporarily parked from subsidy receipts, not recurring investment income.
- EBITDA margin outlook capped at 7%-8%: When asked whether 10% EBITDA was achievable given product mix changes, management explicitly did not confirm it, instead guiding to the 7%-8% range and committing to protect margins only on a best-endeavor basis.
- ₹1,500/tonne EBITDA target: Management stated this number should hold, though energy conservation measures will only "do some sort of help" in covering the urea EBITDA differential, not a quantified offset.
Management: "On the international prices of all the raw material is very volatile, as you might have seen, this current crisis, International crisis, war between the countries and Red Sea crisis. So, this may impact the features in the area of the raw material availability in India and also the pricing. So, it is very difficult to say what way it will go."
Industrial Chemicals & the HX Crystal Shift
- Industrial chemicals market still under pressure: Cheap material from China and other foreign countries continues to depress caprolactam and melamine pricing in the Indian market; the segment is "still not out of woods."
- Capro-Benzene spread squeezed: The spread fell to $620 from $673, with benzene prices up 23% YoY and much higher relative to caprolactam; management is "not very much hopeful for improvement in next quarter."
- Strategic response to spread squeeze: The company is diverting caprolactam production to HX Crystal and importing direct Anone for the caprolactam-1 plant to reduce benzene consumption.
- HX Crystal plant is a structural differentiator: Commissioned October 11, the 20-metric-ton-per-day plant (combined capacity ~10,000 MTPA across both plants) makes GSFC India's sole manufacturer of a product that is currently 100% imported; management framed it as an Atmanirbhar Bharat step.
- Segment-level impact: The sub-segment was at breakeven or a few crores of loss; the HX Crystal plant is expected to wipe out that loss by reducing caprolactam availability in the market and adding a higher-value product.
- Ramp-up on track: Management expects to achieve more than 100% capacity utilization in the second plant within the next month or so.
Management: "HX Crystal which is 100% imported presently in India, nobody else is manufacturing. So, GSFC is only manufacturer of this new product. So, being a foot forward for the Atmanirbhar Bharat, so that is a good step that the company is having."
Volume & Demand Outlook
- Rabi season tailwind: Good monsoon rainfall and enhanced MSPs for six major Rabi crops are expected to boost demand for agri inputs in the upcoming quarter.
- Q3 volume target: Management is targeting sales of 5,00,000 metric tons in Q3 and may surpass that figure; Q4 volumes will depend on phosphoric acid and ammonia prices at that time.
- Full-year volume growth projection: The company is still projecting 20% volume growth for the year.
- Demand for industrial products: Capro-Benzene demand is likely to remain stable to firm during the next quarter.
- Discounts fully withdrawn: Discounts on Ammonium Sulphate and APS have been slowly reduced and are now net zero for both products as the market absorbed the fertilizers.
Projects & Capex
- Near-term capex spend: The second half of FY25 will see ₹400-₹500 crores of spend, concentrated in final payments for the Sulphuric Acid V project and Urea-II revamping, both to be commissioned by March or fiscal year-end.
- Sulphuric Acid V: Under construction, operational by end of FY25; for the October-to-March deficiency period, the company has tied up long-term supply arrangements with other companies at competitive prices.
- Solar power additions: A 15 MW solar plant at Charanka will be commissioned by fiscal year-end, with the entire output for own consumption; additionally, a GIPCL 75 MW plant will supply 37.5 MW to GSFC at rates cheaper than grid power.
- Phosphoric Acid and Sulphuric Acid project: At the initial stage with no direct expenditure impact yet; detail engineering and order placement will trigger payments, with a timeline extending up to March 2027.
- Dahej project: Land has been acquired and studies are underway; management stated it is "immediately starting finalization of which product and project will be installed there," but gave no specific timeline.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Q3 fertilizer sales volume | Target 5,00,000 metric tons, may surpass | Q3 FY25 |
| Full-year volume growth | 20% volume growth | FY25 |
| H2 capex spend | ₹400-₹500 crores | By March 31, 2025 |
| SA5 and Urea-II commissioning | Both plants operational | March 2025 or fiscal year-end |
| Charanka solar plant | 15 MW commissioned for own consumption | End of FY25 |
| HX Crystal plant ramp-up | Achieve >100% capacity utilization in second plant | Within next month or so |
| EBITDA margin range | 7%-8% | Ongoing |
| EBITDA per tonne | ₹1,500/tonne should hold | Ongoing |
| Phosphoric Acid & Sulphuric Acid project | Completion | Up to March 2027 |
Key Metrics
| Metric | Q2 FY25 |
|---|---|
| Standalone PAT | ₹303 cr, highest ever Q2 |
| Standalone PBT | ₹391 cr, second highest ever Q2 |
| First half PAT | ₹395 cr, second highest ever H1 |
| Revenue | -13% YoY; -6% YoY in H1, driven by lower subsidy rates and reduced DAP and urea trading volumes |
| Operating margin | 11%, up from 7% YoY in Q2; 9% in H1, up from 7% YoY |
| Fertilizer output | 1.21 lakh MT, +16% YoY in H1 |
| EBITDA per MT (AS and APS) | ~₹2,500 |
| EBITDA per MT (Urea) | -₹1,000 to -₹1,200, due to unreimbursed fixed cost |
| Employee cost | ₹185 cr, down from ₹250 cr in Q2 FY24 due to one-time provision in prior year |
| Other expenses | ₹234 cr quarterly; ₹443 cr half-yearly, stable |
| Other income | ₹150 cr, primarily dividends and interest on temporary surplus funds |
| Cash and equivalents | >₹2,000 cr |
| Capro-Benzene spread | US$620/MT, down from US$673/MT YoY |
| Phosphoric Acid price (Q3) | US$1,060/MT, up from US$948/MT in Q2 |
| DAP import contracts | ~1.25 lakh MT finalized for Q3 |
| Q3 sales target | ~5,00,000 MT of fertilizers |
| HX Crystal plant capacity | 10,000 MTPA combined; topline of ₹125 cr at full capacity, 30–40% margin, bottom-line improvement of ₹25–30 cr |
| CAPEX spent in H1 FY25 | ₹100–150 cr; ₹400–500 cr expected in H2 |
| Total CAPEX outlay | ₹2,200–2,300 cr (HX Crystal, renewables, SA/PA plants); ₹250 cr spent till Mar 2024 |
| Grid power cost | ₹8–9/unit |